WP
HZNP

Woodline Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Woodline Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-134,800
Closed -$13.9M – 811
2023
Q2 		$13.9M Buy
+134,800
New +$14.2M 0.16% 171

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Woodline Partners's HZNP Position: Q4 2023 in Review

Woodline Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 170,848 shares — an estimated $19.8M sold.

Woodline Partners first reported a position in HZNP in Q4 2019 and held it in 16 quarters. The position peaked at $144M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Woodline Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Woodline Partners sold 170,848 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $19.8M.
  • Woodline Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 16 quarters.
  • Woodline Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $144M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.